Aura Biosciences (AURA) Cash from Operations (2020 - 2026)
Aura Biosciences filings provide 7 years of Cash from Operations readings, the most recent being 29893000.0 for Q1 2026.
- Quarterly Cash from Operations fell 27.99% to 29893000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 91280000.0 through Mar 2026, down 15.97% year-over-year, with the annual reading at 84742000.0 for FY2025, 6.19% down from the prior year.
- Cash from Operations hit 29893000.0 in Q1 2026 for Aura Biosciences, down from 20469000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 10628000.0 in Q2 2022 and bottomed at 29893000.0 in Q1 2026.
- Average Cash from Operations over 5 years is 18405176.47, with a median of 17387000.0 recorded in 2023.
- The largest annual shift saw Cash from Operations crashed 195.89% in 2022 before it grew 14.54% in 2025.
- Aura Biosciences' Cash from Operations stood at 18013000.0 in 2022, then rose by 3.48% to 17387000.0 in 2023, then tumbled by 37.76% to 23952000.0 in 2024, then increased by 14.54% to 20469000.0 in 2025, then tumbled by 46.04% to 29893000.0 in 2026.
- Per Business Quant, the three most recent readings for AURA's Cash from Operations are 29893000.0 (Q1 2026), 20469000.0 (Q4 2025), and 20144000.0 (Q3 2025).